Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients

International Urology and Nephrology

Volumn 46, Issue 1, 2014, Pages 99-106

  Sugimoto, Himiko ^a   Ogawa, Tetsuya ^b   Iwabuchi, Yuko ^a   Otsuka, Kuniaki ^b   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Fibroblast growth factor 23; Hemodialysis; Mortality

Indexed keywords

AGED; C-REACTIVE PROTEIN; CALCIUM; CARDIOVASCULAR DISEASES; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN;

EID: 84893868289     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0386-2     Document Type: Article

References (30)

1. Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494-498
2. Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945-1953 (Pubitemid 43924257)
3. Park SY, Jeong KH, Moon JY et al (2010) The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol 14:239-243
4. Yamashita T, Konishi M, Miyake A et al (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265-28270 (Pubitemid 34966781)
5. Shimada T, Urakawa I, Yamazaki Y et al (2004) FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409-414 (Pubitemid 38084732)
6. Krajisnik T, Bjorklund P, Marsell R et al (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131 (Pubitemid 350056006)
7. Larsson T, Nisbeth U, Ljunggren O et al (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279 (Pubitemid 37449564)
8. Kalantar-Zadeh K, Kuwae N, Regidor DL et al (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771-780 (Pubitemid 44215354)
9. Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004-1013 (Pubitemid 47530570)
10. Taskapan H (2012) Is 24,25(OH)D level really high in dialysis patients with high FGF23 levels? Int Urol Nephrol 44:1135-1144
11. Mirza MA, Larsson A, Lind L et al (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385-390
12. Mirza MA, Hansen T, Johansson L et al (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24:3125-3131
13. Mirza MA, Larsson A, Melhus H et al (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546-551
14. Gutierrez OM, Januzzi JL, Isakova T et al (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545-2552
15. Gutierrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592
16. Echida Y, Ogawa T, Otauka K et al (2012) Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients. Clin Exp Nephrol 16:767-772
17. Tamei N, Ogawa T, Ishida H et al (2011) Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb 18:217-223
18. Kojima F, Uchida K, Ogawa T et al (2008) Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 40:1067-1074
19. Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4:1205-1213
20. Jean G, Terrat JC, Vanel T et al (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792-2796
21. Olauson H, Qureshi AR, Miyamoto T et al (2010) Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant 25:3033-3038
22. Onufrak SJ, Bellasi A, Cardarelli F et al (2009) Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol 169:67-77
23. Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337:116-122
24. Canziani ME, Tomiyama C, Higa A (2011) Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 31:26-32
25. Kirkpantur A, Balci M, Gurbuz OA et al (2011) Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 26:1346-1354
26. Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393-4408
27. Jean G, Bresson E, Terrat JC et al (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24:948-955
28. Nasrallah MM, El-Shehaby AR, Salem MM et al (2010) Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 25:2679-2685
29. Desiardins L, Liabeuf S, Renard C et al (2012) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23:2017-2025
30. Stenvinkel P, Pecoits-Filho R, Lindholm B (2003) Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 7:1927-1939 (Pubitemid 36750489)